Pontocerebellar hypoplasia type 1

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2254OMIM:619304Q04.3
Who is this for?
Show terms as
5Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Pontocerebellar hypoplasia type 1 (PCH1), also known as pontocerebellar hypoplasia with spinal muscular atrophy, is a rare and severe neurodegenerative disorder characterized by underdevelopment (hypoplasia) of the pons and cerebellum — structures in the brainstem and hindbrain critical for motor coordination, balance, and many autonomic functions. The condition combines features of cerebellar hypoplasia with progressive degeneration of anterior horn cells in the spinal cord, similar to what is seen in spinal muscular atrophy (SMA). PCH1 is genetically heterogeneous, with several subtypes identified including PCH1A (caused by mutations in the VRK1 gene), PCH1B (caused by mutations in the EXOSC3 gene, the most common form), PCH1C (EXOSC8), and PCH1D (SLC25A46), among others. Clinical features typically present at birth or in early infancy and include severe generalized muscle weakness and hypotonia, respiratory insufficiency, feeding difficulties, absent or markedly reduced deep tendon reflexes, and progressive microcephaly. Affected infants often show little spontaneous movement, and many develop contractures. Neuroimaging reveals a characteristically small cerebellum and pons, with progressive cerebellar atrophy over time. Additional features may include visual impairment, seizures, and intellectual disability, though the severity of neurological involvement is profound in most cases. The prognosis for PCH1 is generally poor, with many affected children dying in infancy or early childhood due to respiratory failure or other complications. There is currently no cure or disease-modifying treatment available. Management is entirely supportive and may include respiratory support (including mechanical ventilation), nutritional support via gastrostomy tube, physical therapy, and seizure management when needed. Genetic counseling is recommended for affected families.

Also known as:

Clinical phenotype terms— hover any for plain English:

Degeneration of anterior horn cellsHP:0002398Hypoplasia of the ponsHP:0012110Tongue fasciculationsHP:0001308
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

1 event
Dec 2024Education & Care in RARE: Efficacy of Targeted Psychoeducational Intervention Among Pediatric Rare Disease Patients

Medical University of Vienna — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Pontocerebellar hypoplasia type 1.

View clinical trials →

No actively recruiting trials found for Pontocerebellar hypoplasia type 1 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Pontocerebellar hypoplasia type 1 community →

Specialists

5 foundView all specialists →
M&
Mario Škarica
Specialist
1 Pontocerebellar hypoplasia type 1 publication
S&
Sasha A Živković
Specialist
1 Pontocerebellar hypoplasia type 1 publication
GA
Gyula Acsadi
DETROIT, MI
Specialist
1 Pontocerebellar hypoplasia type 1 publication
JA
Julia Vodopiutz, MD apProf
Graz, Austria
Specialist

Rare Disease Specialist

15 Pontocerebellar hypoplasia type 1 publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Pontocerebellar hypoplasia type 1.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Pontocerebellar hypoplasia type 1Forum →

No community posts yet. Be the first to share your experience with Pontocerebellar hypoplasia type 1.

Start the conversation →

Latest news about Pontocerebellar hypoplasia type 1

Disease timeline:

New trial: Education & Care in RARE: Efficacy of Targeted Psychoeducational Intervention Among Pediatric Rare D

Phase NA trial recruiting. Education & Care in RARE

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Pontocerebellar hypoplasia type 1

What is Pontocerebellar hypoplasia type 1?

Pontocerebellar hypoplasia type 1 (PCH1), also known as pontocerebellar hypoplasia with spinal muscular atrophy, is a rare and severe neurodegenerative disorder characterized by underdevelopment (hypoplasia) of the pons and cerebellum — structures in the brainstem and hindbrain critical for motor coordination, balance, and many autonomic functions. The condition combines features of cerebellar hypoplasia with progressive degeneration of anterior horn cells in the spinal cord, similar to what is seen in spinal muscular atrophy (SMA). PCH1 is genetically heterogeneous, with several subtypes iden

How is Pontocerebellar hypoplasia type 1 inherited?

Pontocerebellar hypoplasia type 1 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Pontocerebellar hypoplasia type 1 typically begin?

Typical onset of Pontocerebellar hypoplasia type 1 is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Pontocerebellar hypoplasia type 1?

5 specialists and care centers treating Pontocerebellar hypoplasia type 1 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.